Downstream processing of co-amorphous olanzapine

Abstract of poster presented at the 12th PBP World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien, Austria, 11-14 May 2021 (virtual meeting)N/

Addressing drug solubility problems : a case-study

Poster presented at the 10th iMed.ULisboa Postgraduate Students Meeting & 3rd i3DU Meeting. 24-25 Julho 2018, LisboaN/

Development of an at-line method to monitor the conversion of amorphous into crystalline Olanzapine, in dry blends of wet masses

Abstract of the poster presented at the 3rd European Conference on Pharmaceutics. 25-26 march 2019, Bologne, ItalyN/

Assessment of the stability of co-amorphous Olanzapine in tablets

Abstract of the poster presented at the 4th International Congress of CiiEM - "Health, Well-being and Ageing in the XXI Century." 2-5 June 2019, Monte de Caparica, PortugalN/

Drug-excipient and drug-drug mixtures : a pathway for the production of co-amorphous entities

Abstract of the communication presented at the 3rd International Congress of CiiEM ‘Research and Innovation in Human and Health Sciences’. Campus Egas Moniz, Caparica, Portugal, June 20-22, 2018N/

Cohesiveness of powdered co-amorphous Olanzapine and impact on tablet production

Communication abstract: Proceedings of the 5th International Congress of CiiEM - Reducing inequalities in Health and Society, held at Egas Moniz’ University Campus in Monte de Caparica, Almada, from June 16th to 18th, 2021.This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.The evaluation of the processability of co-amorphous mixtures is of paramount importance since these systems are increasingly used to address the poor solubility presented by most of the drugs in research and development. This work shows that co-amorphous olanzapine powders present higher cohesiveness than their crystalline counterpart and resulted in the production of tablets with a higher tensile strength and a slower release of the drug. As a result, this work demonstrates that despite the solubility advantages of co-amorphous mixtures, consideration should be given to the downstream processing of formulations containing such materials.info:eu-repo/semantics/publishedVersio

Co-amorphization of olanzapine for solubility enhancement

Communication presented at the 3rd International Congress of CiiEM - Research and Innovation in Human and Health Sciences. Monte da Caparica, Portugal, 20-22 June 2018N/

Solid state conversion of olanzapine during tableting

Abstract of poster presented at the 12th PBP World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology, Wien, Austria, 11-14 May 2021 (virtual Meeting)N/

Comparison of the amorphization ability of two polymorphic forms of olanzapine

Abstract of the poster presented at the 4th International Congress of CiiEM - "Health, Well-being and Ageing in the XXI Century". 2-5 June 2019, Campus Egas Moniz, Monte de Caparica, PortugalN/

In-situ co-amorphization of olanzapine in pellets

Poster presented at the 13th PBP World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology. Rotterdam, The Netherlands, 28-31 March 2022N/